Please wait a minute...
Reviews in Cardiovascular Medicine  2021, Vol. 22 Issue (3): 635-648     DOI: 10.31083/j.rcm2203074
Special Issue: Atrial fibrillation and ischemic heart disease
Review Previous articles | Next articles
Atrial fibrillation and coronary artery disease: a review on the optimal use of oral anticoagulants
Pier Paolo Bocchino1, Filippo Angelini1, Elisabetta Toso1, *()
1Division of Cardiology, Department of Medical Sciences, University of Turin, ''Città della Salute e della Scienza'' Hospital, 10126 Turin, Italy
Download:  PDF(164KB)  ( 524 ) Full text   ( 49 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
Atrial fibrillation (AF) represents the most prevalent supraventricular arrhythmia in adults population and up to 15% of AF patients undergo percutaneous coronary intervention (PCI) for coronary artery disease (CAD) during their life. While oral anticoagulants (OACs) exert a protective effect in the setting of stroke prevention and systemic embolization in AF patients, patients undergoing PCI are recommended to receive dual antiplatelet therapy (DAPT) to reduce the risk of cardiovascular death, recurrent myocardial infarction and stent thrombosis. When these two scenarios coexist, as all antithrombotic regimens are burdened by an increase in bleeding risk, antithrombotic regimen and therapy duration must be cautiously tailored on individual patients' characteristics after attentive assessment of ischemic and bleeding risks. Non-vitamin K oral anticoagulants (NOACs), directly inhibiting either thrombin or factor Xa of the coagulation cascade, have progressively replaced warfarin as first choice OACs in several scenarios; recently, randomized controlled trials have compared antithrombotic regimens including NOAC molecules vs vitamin K antagonists in AF patients undergoing PCI to explore the efficacy and safety of NOACs in this setting. These studies have provided a deeper understanding of antithrombotic therapy after PCI in AF patients and have been promptly implemented by the most recent guidelines on AF and CAD management. The aim of the present review was to summarize the current available literature on the perils and benefits of individual OAC molecules in AF patients with acute and/or chronic coronary syndromes in order to provide guidance on the optimal use of OACs in these complex scenarios.
Key words:  Atrial fibrillation      Oral anticoagulation      Coronary artery disease      VKA      NOAC     
Submitted:  26 May 2021      Revised:  01 July 2021      Accepted:  02 July 2021      Published:  24 September 2021     
*Corresponding Author(s):  Elisabetta Toso     E-mail:  elisabetta.toso@gmail.com

Cite this article: 

Pier Paolo Bocchino, Filippo Angelini, Elisabetta Toso. Atrial fibrillation and coronary artery disease: a review on the optimal use of oral anticoagulants. Reviews in Cardiovascular Medicine, 2021, 22(3): 635-648.

URL: 

https://rcm.imrpress.com/EN/10.31083/j.rcm2203074     OR     https://rcm.imrpress.com/EN/Y2021/V22/I3/635

[1] Andrea Messori, Laura Bartoli, Elisa Ferracane, Sabrina Trippoli. Medical therapy, radiofrequency ablation or cryoballoon ablation as first-line treatment for paroxysmal atrial fibrillation: interpreting efficacy through restricted mean survival time and network meta-analysis[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 557-561.
[2] Călin Pop, Diana Țînț, Antoniu Petris. Management of antithrombotic therapy in patients with atrial fibrillation and acute coronary syndromes[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 659-675.
[3] Anggoro Budi Hartopo, Jajah Fachiroh, Ira Puspitawati, Fatwa Sari Tetra Dewi. Serum endothelin-1 level positively correlates with waist and hip circumferences in stable coronary artery disease patients[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 919-924.
[4] Yanwei Du, Yanan Hu, Naiyan Wen, Shuang Fu, Guorong Zhang, Li Li, Tiantian Liu, Xuejiao Lv, Wenfeng Zhang. Abnormal expression of TGFBR2, EGF, LRP10, and IQGAP1 is involved in the pathogenesis of coronary artery disease[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 947-958.
[5] Xiao-Fei Wang, Meng-Cheng Xu, Cheng-Yu Mao, En-Zhou, Qing He, Xing-Qian Qu, Yu-Qi Fan, Chang-Qian Wang, Jun-Feng Zhang. Predictive and prognostic value of v-set and transmembrane domain-containing 1 expression in monocytes for coronary artery disease[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 1009-1017.
[6] Chi Zhang, Wei-Wei Wang, Mang-Mang Pan, Zhi-Chun Gu. Simulation of anticoagulation in atrial fibrillation patients with rivaroxaban—from trial to target population[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 1019-1027.
[7] Darryl Wan, Jason Andrade, Zachary Laksman. Thromboembolic risk stratification in atrial fibrillation—beyond clinical risk scores[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 353-363.
[8] Nicholas C. Sanderson, William A. E. Parker, Robert F. Storey. Ticagrelor: clinical development and future potential[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 373-394.
[9] Catrin Sohrabi, Syed Ahsan, Alexandros Briasoulis, Emmanuel Androulakis, Gerasimos Siasos, Neil T Srinivasan, Nikolaos Papageorgiou. Contemporary management of heart failure patients with reduced ejection fraction: the role of implantable devices and catheter ablation[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 415-428.
[10] Andrea Saglietto, Vittorio Varbella, Andrea Ballatore, Henri Xhakupi, Gaetano Maria De Ferrari, Matteo Anselmino. Prognostic implications of atrial fibrillation in patients with stable coronary artery disease: a systematic review and meta-analysis of adjusted observational studies[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 439-444.
[11] Izzat AlAwwa, Akram Saleh, Ayman M. Wahbeh, Shatha Jallad, Sarah Ibrahim, Ahmad Al-Awwa, Randa I. Farah. Accuracy and feasibility of portable blood pressure monitoring in the detection of atrial fibrillation in hemodialysis patients[J]. Reviews in Cardiovascular Medicine, 2021, 22(1): 225-229.
[12] Yin-jun Mao, Hang Wang, Jian-xing Chen, Pin-fang Huang. Meta-analysis of medical management versus catheter ablation for atrial fibrillation[J]. Reviews in Cardiovascular Medicine, 2020, 21(3): 419-432.
[13] Hai-Fu Zhang, Qin-Xia Zhang, Yuan-Yuan Zhang, Dong Yang, Zhao Xu, Qi-Bin Jiao, Xing-Wei Zhang. Efficacy and safety of left atrial appendage occlusion in atrial fibrillation patients with chronic kidney disease: a systematic review and meta-analysis[J]. Reviews in Cardiovascular Medicine, 2020, 21(3): 443-451.
[14] Meer Fakhry, Mandeep S. Sidhu, Sripal Bangalore, Roy O. Mathew. Accelerated and intensified calcific atherosclerosis and microvascular dysfunction in patients with chronic kidney disease[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 157-162.
[15] Anthony (Ming-yu) Chuang, Mau T Nguyen, Woon-Man Kung, Sam Lehman, Derek P Chew. High-sensitivity troponin in chronic kidney disease: Considerations in myocardial infarction and beyond[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 191-203.
No Suggested Reading articles found!